☆ 4.7 Review

Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors

PHARMACOLOGY & THERAPEUTICS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Editorial Material Pharmacology & Pharmacy

An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease

Yu Kurata et al.

Summary: Experts evaluated the pharmacology of roxadustat and emphasized its potential as an attractive alternative treatment for anemia in CKD patients, especially for those with ESA hyporesponsiveness due to impaired iron utilization. Proper selection of target patients and its correct usage are crucial for the successful application of roxadustat in clinical settings.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

添加到收藏夹

Article Urology & Nephrology

Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)

Sishir Gang et al.

Summary: This study demonstrates that desidustat is noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and is well-tolerated.

AMERICAN JOURNAL OF NEPHROLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)

Dhananjai Agrawal et al.

Summary: Desidustat is non-inferior to darbepoetin in the treatment of anemia due to non-dialysis dependent CKD and it is well-tolerated.

AMERICAN JOURNAL OF NEPHROLOGY (2022)

添加到收藏夹

Article Urology & Nephrology

Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study

Steven Fishbane et al.

Summary: Roxadustat effectively increases hemoglobin in patients with dialysis-dependent CKD, and its adverse event profile is comparable to that of epoetin alfa.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

添加到收藏夹

Article Hematology

Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats

Kristine Jimenez et al.

Summary: Iron deficiency not only causes anemia but also leads to thrombocytosis and an increased risk of blood clots. Animal studies show that iron deficiency increases thrombosis and affects platelet function. Iron replacement therapy can reverse these changes, making it an effective strategy for preventing thrombotic diseases related to iron deficiency.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Urology & Nephrology

Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis

Tadao Akizawa et al.

Summary: This study demonstrated that Molidustat maintained hemoglobin levels in patients receiving dialysis and was noninferior to darbepoetin in terms of efficacy.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Urology & Nephrology

A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study

Tadao Akizawa et al.

Summary: Enarodustat was found to be noninferior to darbepoetin alfa in the treatment of anemia in CKD patients receiving maintenance hemodialysis, showing good tolerability over a 24-week period.

KIDNEY DISEASES (2021)

添加到收藏夹

Review Urology & Nephrology

Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors

Desmond Y. H. Yap et al.

Summary: Renal anaemia is a common and important complication in patients with chronic kidney disease, and the use of HIF-PHI has emerged as a novel approach for its management. However, when prescribing this class of drug, potential benefits and harms need to be carefully considered.

NEPHROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Roxadustat for CKD-related Anemia in Non-dialysis Patients

Daniel W. Coyne et al.

Summary: The global Phase 3 randomized study on roxadustat showed significant improvements in hemoglobin levels for patients with CKD-related anemia not on dialysis, with a high proportion of patients achieving a hemoglobin response. Roxadustat was well-tolerated with comparable incidences of adverse events between the roxadustat and placebo groups.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Urology & Nephrology

Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial

Masaomi Nangaku et al.

Summary: The study showed that oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients. The mean hemoglobin levels in both treatment groups were within the target range, and there was no meaningful difference in the frequencies of adverse events.

AMERICAN JOURNAL OF NEPHROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis

Ajay K. Singh et al.

Summary: Among patients with CKD undergoing dialysis, daprodustat was found to be noninferior to ESAs in terms of change in hemoglobin levels and cardiovascular outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis

Ajay K. Singh et al.

Summary: This study compared the efficacy and safety of daprodustat and darbepoetin alfa in treating anemia in CKD patients not undergoing dialysis. The change in hemoglobin levels and cardiovascular outcomes were similar between the two groups during the study period.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Urology & Nephrology

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

Steven Fishbane et al.

Summary: Roxadustat effectively increased hemoglobin levels and reduced the risk of red blood cell transfusion in non-dialysis-dependent CKD patients, with an adverse event profile similar to that of placebo.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Transplantation

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)

Evgeny Shutov et al.

Summary: The study demonstrated that Roxadustat is more effective than placebo in treating anemia in patients with chronic kidney disease. The treatment group showed significantly higher Hb response rate and Hb change from baseline compared to the placebo group.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Transplantation

Roxadustat for anemia in patients with end-stage renal disease incident to dialysis

Robert Provenzano et al.

Summary: This study demonstrated the efficacy and safety of roxadustat in treating chronic kidney disease-related anemia. Roxadustat was shown to be as effective as epoetin alfa in correcting and maintaining hemoglobin levels, with comparable rates of adverse events.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Transplantation

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study

Masaomi Nangaku et al.

Summary: The study compared the efficacy and safety of vadadustat with darbepoetin alfa in Japanese anemic patients on hemodialysis. Vadadustat was found to be noninferior to darbepoetin alfa in maintaining hemoglobin levels within the target range, with similar adverse events observed in both groups. This suggests that vadadustat can be a viable alternative to ESA in managing anemia in Japanese hemodialysis patients.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Urology & Nephrology

Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD

Masaomi Nangaku et al.

Summary: In Japanese patients with NDD-CKD, vadadustat was found to be noninferior to darbepoetin alfa in terms of average hemoglobin levels and was well tolerated up to week 52. These results suggest that vadadustat may be a potential treatment option for anemia in this patient population.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone

Mark R. Hanudel et al.

Summary: The investigational drug Vadadustat has shown promising effects on improving anemia and kidney function in CKD models, independently of ERFE, and has also been shown to decrease FGF23 levels. Further research is needed to understand how Vadadustat affects CKD progression in humans.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD

Glenn M. Chertow et al.

Summary: Vadadustat, compared to darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not for cardiovascular safety in patients with NDD-CKD.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis

Kai-Uwe Eckardt et al.

Summary: Vadadustat, an oral prolyl hydroxylase inhibitor, was found to be noninferior to darbepoetin alfa in terms of cardiovascular safety and hemoglobin concentration in anemia patients with CKD undergoing dialysis, based on two phase 3 trials.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Urology & Nephrology

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study

Chaim Charytan et al.

Summary: This study demonstrated that roxadustat was noninferior to epoetin alfa in treating anemia in end-stage kidney disease patients for up to 52 weeks, with comparable tolerability between the two treatments.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Urology & Nephrology

A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study

Tadao Akizawa et al.

Summary: Enarodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, showed comparable efficacy to darbepoetin alfa in managing anemia in Japanese patients with chronic kidney disease. The drug was also found to be safe with no identified new safety concerns compared to darbepoetin alfa.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)

Botond Csiky et al.

Summary: Roxadustat was shown to be non-inferior to ESA in maintaining hemoglobin levels and superior to ESA in decreasing LDL cholesterol levels. Common TEAEs in both treatment groups included hypertension, arteriovenous fistula thrombosis, headache, and diarrhea.

ADVANCES IN THERAPY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies

Jonathan Barratt et al.

Summary: This integrated phase 3 analysis evaluated the efficacy and cardiovascular safety of roxadustat compared to ESA in dialysis-dependent patients with anemia of CKD. Results showed non-inferiority of roxadustat to ESA in terms of hemoglobin change and risks for cardiovascular events, with consistent safety profiles between the two treatment groups. Roxadustat represents a promising oral alternative to ESA for managing anemia of CKD in dialysis-dependent patients.

ADVANCES IN THERAPY (2021)

添加到收藏夹

Article Urology & Nephrology

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial

Hiroyasu Yamamoto et al.

Summary: In the MIYABI ND-C study, Molidustat was shown to be an efficacious and generally well-tolerated alternative to darbepoetin for the treatment of renal anemia in Japanese patients who were not undergoing dialysis and were not receiving ESA treatment.

AMERICAN JOURNAL OF NEPHROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study

Hiroyasu Yamamoto et al.

Summary: The study demonstrated that molidustat was well tolerated and effective in Japanese patients with renal anemia not undergoing dialysis and previously treated with ESAs, maintaining Hb levels within the target range. Molidustat was shown to be a good alternative to darbepoetin.

AMERICAN JOURNAL OF NEPHROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD Pooled Results of Three Randomized Clinical Trials

Robert Provenzano et al.

Summary: Roxadustat demonstrated superior efficacy in increasing hemoglobin levels compared to placebo, while also reducing the need for red blood cell transfusions. Furthermore, Roxadustat showed non-inferiority to placebo in terms of cardiovascular safety, including major adverse cardiovascular events.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation

Yue Zhou et al.

Summary: Roxadustat showed significant anti-anemia effects in patients with erythropoietin hypo-responsiveness, although complications such as malnutrition and inflammation may interfere with its effectiveness. Changes in serum indicators and nutritional status could impact the treatment outcome.

INTERNAL AND EMERGENCY MEDICINE (2021)

添加到收藏夹

Article Transplantation

Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)

Jonathan Barratt et al.

Summary: Roxadustat is a viable option for treating anemia in NDD CKD patients, maintaining Hb levels for up to 104 weeks.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Hematology

A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients

Yoshiharu Tsubakihara et al.

THERAPEUTIC APHERESIS AND DIALYSIS (2020)

添加到收藏夹

Review Urology & Nephrology

The multifaceted role of iron in renal health and disease

Rachel P. L. van Swelm et al.

NATURE REVIEWS NEPHROLOGY (2020)

添加到收藏夹

Article Urology & Nephrology

Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage

Marie Ito et al.

KIDNEY INTERNATIONAL (2020)

添加到收藏夹

Article Urology & Nephrology

Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice

Mai Sugahara et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Iron-Deficiency and Estrogen Are Associated With Ischemic Stroke by Up-Regulating Transferrin to Induce Hypercoagulability

Xiaopeng Tang et al.

CIRCULATION RESEARCH (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis

Junduo Liu et al.

PHARMACOLOGICAL RESEARCH (2020)

添加到收藏夹

Article Urology & Nephrology

Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia A Randomized, Double-Blind, Phase 3 Trial

Tadao Akizawa et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

添加到收藏夹

Article Physiology

Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease

Lisa Uchida et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2020)

添加到收藏夹

Article Urology & Nephrology

Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis

Gunnar Schley et al.

KIDNEY INTERNATIONAL (2019)

添加到收藏夹

Article Medicine, General & Internal

Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis

N. Chen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis

N. Chen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Cell Biology

Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism

Xingzhong Zhang et al.

CELL METABOLISM (2019)

添加到收藏夹

Article Urology & Nephrology

Effects of Molidustat in the Treatment of Anemia in CKD

Iain C. Macdougall et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)

添加到收藏夹

Editorial Material Urology & Nephrology

The noblesse of kidney physiology

Kai-Uwe Eckardt

KIDNEY INTERNATIONAL (2019)

添加到收藏夹

Article Urology & Nephrology

A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial

Tadao Akizawa et al.

AMERICAN JOURNAL OF NEPHROLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study

Deven V. Parmar et al.

AMERICAN JOURNAL OF NEPHROLOGY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

Amit A. Joharapurkar et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

添加到收藏夹

Article Urology & Nephrology

HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease

Andre Kraus et al.

KIDNEY INTERNATIONAL (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver

Seonghwan Hwang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2017)

添加到收藏夹

Review Urology & Nephrology

Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease

Mai Sugahara et al.

KIDNEY INTERNATIONAL (2017)

添加到收藏夹

Article Urology & Nephrology

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease

Edouard R. Martin et al.

AMERICAN JOURNAL OF NEPHROLOGY (2017)

添加到收藏夹

Article Urology & Nephrology

Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia

Louis Holdstock et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)

添加到收藏夹

Article Urology & Nephrology

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

Anatole Besarab et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)

添加到收藏夹

Article Transplantation

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

Anatole Besarab et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)

添加到收藏夹

Article Urology & Nephrology

Activation of Hypoxia-Inducible Factors Prevents Diabetic Nephropathy

Lina Nordquist et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)

添加到收藏夹

Article Endocrinology & Metabolism

HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction

Lea Rahtu-Korpela et al.

DIABETES (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Prevalence of Anemia in Chronic Kidney Disease in the United States

Melissa E. Stauffer et al.

PLOS ONE (2014)

添加到收藏夹

Article Chemistry, Medicinal

Inhibition of Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Oxygen Sensors: Tricking the Body into Mounting Orchestrated Survival and Repair Responses

Michael H. Rabinowitz

JOURNAL OF MEDICINAL CHEMISTRY (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia

Guo-Min Shen et al.

BIOCHEMICAL JOURNAL (2012)

添加到收藏夹

Article Hematology

Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis

Maria Mastrogiannaki et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

添加到收藏夹

Article Medicine, Research & Experimental

Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis

Qingdu Liu et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

添加到收藏夹

Article Cell Biology

Intestinal Hypoxia-inducible Transcription Factors Are Essential for Iron Absorption following Iron Deficiency

Yatrik M. Shah et al.

CELL METABOLISM (2009)

添加到收藏夹

Article Medicine, General & Internal

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Marc A. Pfeffer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Multidisciplinary Sciences

Evidence for a Lack of a Direct Transcriptional Suppression of the Iron Regulatory Peptide Hepcidin by Hypoxia-Inducible Factors

Melanie Volke et al.

PLOS ONE (2009)

添加到收藏夹

Article Multidisciplinary Sciences

Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model

W. M. Bernhardt et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

添加到收藏夹

Article Hematology

Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure

Yoji Andrew Minamishima et al.

BLOOD (2008)

添加到收藏夹

Article Urology & Nephrology

Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury

Peter Hill et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)

添加到收藏夹

Article Urology & Nephrology

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

Lynda A. Szczech et al.

KIDNEY INTERNATIONAL (2008)

添加到收藏夹

Article Physiology

Stable expression of HIF-1α in tubular epithelial cells promotes interstitial fibrosis

Kuniko Kimura et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Acute postnatal ablation of Hif-2α results in anemia

Michaela Gruber et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

添加到收藏夹

Article Medicine, General & Internal

Correction of anemia with epoetin alfa in chronic kidney disease

Ajay K. Singh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

添加到收藏夹

Article Medicine, General & Internal

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Tilman B. Drueke et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

添加到收藏夹

Article Urology & Nephrology

Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure

Wanja M. Bernhardt et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)

添加到收藏夹

Article Urology & Nephrology

Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis

T Tanaka et al.

KIDNEY INTERNATIONAL (2005)

添加到收藏夹

Article Physiology

Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity

T Tanaka et al.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)

添加到收藏夹

Article Hematology

FEF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner

M Scortegagna et al.

BLOOD (2005)

添加到收藏夹

Review Biochemistry & Molecular Biology

Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation

CJ Hu et al.

MOLECULAR AND CELLULAR BIOLOGY (2003)

添加到收藏夹

Article Urology & Nephrology

Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients

K Kalantar-Zadeh et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2003)

添加到收藏夹

Article Biochemistry & Molecular Biology

HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia

E Berra et al.

EMBO JOURNAL (2003)

添加到收藏夹

Article Urology & Nephrology

Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats

M Matsumoto et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)

添加到收藏夹

Article Multidisciplinary Sciences

HIFα targeted for VHL-mediated destruction by proline hydroxylation:: Implications for O2 sensing

M Ivan et al.

SCIENCE (2001)

添加到收藏夹

Article Multidisciplinary Sciences

Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

P Jaakkola et al.

SCIENCE (2001)

添加到收藏夹

Article Biochemistry & Molecular Biology

Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency

CK Mukhopadhyay et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.